Fetcroja

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued[2] / amended on	Product Information affected[3]	Summary
R/0022	Renewal of the marketing authorisation.	14/11/2024	13/01/2025	SmPC, Annex II and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Fetcroja in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. SmPC section 4.8 is updated to include Chromaturia

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

					adverse reaction with frequency “not known” and SmPC section 5.1. is updated to include updated information regarding the minimum inhibitory concentration.
IA/0021	A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	28/06/2024	n/a		
IA/0020	A.7 - Administrative change - Deletion of manufacturing sites	28/06/2024	13/01/2025	Annex II and PL	
PSUSA/10849 /202311	Periodic Safety Update EU Single assessment - cefiderocol	13/06/2024	n/a		PRAC Recommendation - maintenance
IB/0019	B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method	26/03/2024	n/a		
II/0017	Update of sections 4.5 and 5.2 of the SmPC in order to update drug-drug interaction information with CYP3A4 based on final results from study 2136R2118; this is a Phase 1, open-label, 1-sequence crossover, drug-drug interaction study to assess the effect of repeated doses of cefiderocol on the pharmacokinetics of midazolam in healthy adult participants. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance	14/12/2023	16/02/2024	SmPC	Based on in vitro studies and two phase 1 clinical studies, no significant drug-drug interactions are anticipated between cefiderocol and substrates, inhibitors or inducers of cytochrome P450 enzymes (CYPs) or transporters. For more information, please refer to the Summary of Product Characteristics.

	data				
II/0016	Update of sections 4.2 and 6.2 of the SmPC in order to update the information on incompatibility in line with the PRAC recommendation adopted for EMEA/H/C/PSUSA/00010849/202211. The package leaflet was revised accordingly, to introduce information intended for healthcare professionals. C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH	05/10/2023	16/02/2024	SmPC	If treatment with a combination of another medicinal product and Fetcroja is unavoidable, administration should not occur in the same syringe or in the same infusion solution. It is recommended to adequately flush intravenous lines between administration of different medicinal products.
IAIN/0015	B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer	23/06/2023	n/a		
PSUSA/10849 /202211	Periodic Safety Update EU Single assessment - cefiderocol	19/06/2023	n/a		PRAC Recommendation - maintenance
IAIN/0014/G	This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release -	07/03/2023	16/02/2024	SmPC, Annex II, Labelling and PL	

	Not including batch control/testing				
PSUSA/10849 /202111	Periodic Safety Update EU Single assessment - cefiderocol	23/06/2022	17/08/2022		Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10849/202111.
IB/0012/G	This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	20/05/2022	n/a		
IB/0010/G	This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process	07/03/2022	n/a		

	of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate				

	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation				

	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation				
	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation				
	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation				
	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation				
	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation				
	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation				
	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation				
	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation				
	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation				
	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation				
	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting				

	material/intermediate/reagent - Other variation B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation				
II/0006/G	This was an application for a group of variations. Update of section 4.5 of the SmPC to include new information on interactions with other medicinal products, based on data from the final reports from the in vitro RIS correlation study S-649266-PF-415-N (REC 003), to address CYP3A4 induction by cefiderocol and from the final report of in vitro study S-649266-CPK-008-C to investigate the DDI between cefiderocol as a CYP3A4 inducer and Midazolam using physiologically based pharmacokinetic model.	24/02/2022	17/08/2022	SmPC	SmPC new text […] 4.5 Interaction with other medicinal products and other forms of interaction Cefiderocol induces CYP3A4 in vitro. Therefore, the metabolism of co-administered medicinal products that are substrates of CYP3A4 is expected to increase and lead to decreased systemic exposure of these medicinal products. If cefiderocol is administered together with substrates of CYP3A4, the patients should be monitored for decreased efficacy of the concomitant drug. The effect of systemic hormonal contraceptives may be reduced; thus it is

	C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority				recommended to use an additional contraceptive method during and until 28 days after treatment with cefiderocol. As the in vitro CYP3A4 induction by cefiderocol is PXR mediated, other PXR inducible proteins may also be induced, for example the CYP2C family and P-gp. The clinical relevance of this induction is unknown. As a consequence, if cefiderocol is administered together with substrates of the CYP2C family or P-gp, the patients should be monitored for decreased efficacy of the concomitant drug. Based on in vitro studies and one phase 1 clinical evaluation no significant drug-drug interactions are anticipated between cefiderocol and substrates or inhibitors of cytochrome P450 enzymes (CYPs) or transporters (see section 5.2), except for the above-mentioned induction of CYP3A4, CYP2C and P-gp. […] For more information, please refer to the Summary of Product Characteristics.
IAIN/0011	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	03/02/2022	n/a		
N/0008	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	21/01/2022	17/08/2022	PL	
PSUSA/10849 /202105	Periodic Safety Update EU Single assessment - cefiderocol	02/12/2021	n/a		PRAC Recommendation - maintenance
IAIN/0007/G	This was an application for a group of variations.	18/11/2021	n/a		

	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site				
IAIN/0004/G	This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	15/06/2021	n/a		
PSUSA/10849 /202011	Periodic Safety Update EU Single assessment - cefiderocol	10/06/2021	n/a		PRAC Recommendation - maintenance
IAIN/0002/G	This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	27/08/2020	n/a		

IAIN/0001	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	02/07/2020	21/06/2021	Annex II and PL	